# Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy

> **NCT07067268** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 76 (estimated)

## Conditions studied

- Nasopharyngeal Cancinoma (NPC)

## Interventions

- **DRUG:** Adjuvant therapy

## Key facts

- **NCT ID:** NCT07067268
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-14
- **Primary completion:** 2026-09
- **Final completion:** 2029-12
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07067268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07067268, "Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07067268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*